Retrospective analysis of local control and cosmetic outcome of 147 periorificial XXXX of the face treated with low-dose rate interstitial brachytherapy.

@entity1 @entity5 @entity1489 @entity957 @entity189 @entity1491
PURPOSE: @entity1489 is the most common @entity5 in white populations. We evaluated the local cure rate and cosmetic outcome of @entity1 with @entity1491 ( @entity1491 ) or @entity957 ( @entity957 ) of the face treated with low-dose rate brachytherapy. METHODS AND MATERIALS: Between February 1990 and May 2000, 147 @entity189 in 132 @entity1 were treated by (192)Ir wire implantation. Side effects of brachytherapy were noted. Follow-up was 2 years or more. Locoregional recurrence-free survival (LRFS) and overall survival were recorded. Group A included @entity1 treated by primary brachytherapy, and Group B included those treated after recurrence. RESULTS: A total of 121 @entity189 were BCCs (82.3%) and 26 were SCCs (17.7%); the median @entity5 size was 10 mm. Of the @entity5 , 86 (58.5%) were in @entity1 and 61 (41.5%) were in @entity1 ; the median age was 71 years. Group A comprised 116 lesions (78.9%), and Group B, 31 (21.1%). There were 17 relapses (11.6%) after a median follow-up of 72 months: 12 local, 4 nodal, and 1 local and nodal. Locoregional-free survival was 96.6% at 2 years and 87.3% at 5 years. Five-year LRFS was 82.6% in @entity1 and 93.3% in @entity1 (p = 0.027). After adjustment for gender, LRFS was better after primary treatment than after recurrence (hasard ratio HR, 2.91; 95% confidence interval, 1.06-8.03; p  = 0.039). Five-year LRFS was 90.4% for @entity1491 and 70.8% for @entity957 (p = 0.03). There were no Grade 3 complications. CONCLUSIONS: Low-dose rate brachytherapy offers good local control and cosmetic outcome in @entity1 with @entity1489 , with no Grade 3 complications. Brchytherapy is more efficient when used as primary treatment.
